Appendix B – Requisition Form for Carbapenemase-Producing Organisms (CPO) Testing

BC Centre for Disease Control	Public H 655 West 12th www.bccdc.ca	Avenu	e, Vancouve			Bacteriolog papenemase Pro			-	
Section 1 - Patient Inform		, paul								LAD.
PERSONAL HEALTH NUMBER (o	rout-of province He	alth Nurr	berand	DOB (no/	MIMIM/YYYY)	GENDER M F	ППМК	DATE RECEIVE	0	
PATIENT SURNAME				PATIENT FIR	ST AND N	AIDDLE NAME	LIONK		BODAT	ORV
ADDRESS			CITY POSTAL CODE			TAL CODE	LABORATORY USE ONLY			
Section 2 - Submitting La	boratory D	etails						,		
CONTACT PERSON				HOSPITAL (tame and ad	dress for report delivery)		SAMPLE REF.	NO.	
TELEPHONE NUMBER				PHSA CLIENT N	D.			DATE COLLECTED (DO/MMM/YYYY)		
ADDITIONAL COPIES TO:										
Section 3 - Specimen Det	ails							•		
ORGANISM IDENTIFICATION:	Genus			Spe	cies		SPECIMEN	respirator	_	lood
SCREENING ISOLATE		CLINICAL ISOLATE CONTACT TRACING		SOUNCE	urine	_	vound ther:			
PREVIOUS CPO SCREENIN	G: 🗆 1	ю	YES	DATE:				rectal		tneri
Automated Antibiogram:										
Antibiotic	MIC	Inter	pretation	(S, I, R)	Antib	lotic	MIC	Interpret	ation (S,	l, R)
Ampicillin		S□	10	R 🗆	Genta	micin		S	П	R□
Ampicillin/Clavulanate		S	I		lmipe	nem		S 🗆		R 🖂
Aztreonam		S	ı	R 🗆	Levof	loxacin		S		R 🖂
Amikacin		S	I	R 🗆	Merop	penem		5 🗆		R 🖂
Cefazolin		S	I	R □	Minoc	cycline		S 🗆		R 🗆
Cefepime		5 🗆	I	R 🗆	Nitrof	urantoin		S 🗆	1	R 🔲
Cefoxitin		S	I	R 🗆	Peflox	acin		S		R 🗆
Cefpodoxime		S	I] R_	Pipera	ecillin		S 🗆		R 🖂
Ceftazidime		S	I	R □	Pipera	acillin/Tazobactam		5 🗆		R 🖂
Cefixime		S	1	R □	Rifam	pin		S 🗆		R 🔲
Ceftriaxone		S	I] R_	Ticarc	illin		S 🗆	П	R 🗆
Cephalothin/Cephalexin		5	ı] R_	Ticarc	illin/Clavulanic Acid		S		R 🖂
Ciprofloxacin		S	1	R □	Tigec	ycline		S 🗆		R 🗆
Colistin		S	I	R □	Tobra	mycin		S 🗆	П	R 🗆
Ertapenem		S	1	R □	Trime	thoprim/Sulfamethoxaz	role	S 🗆		R 🗆
		OR, S	See attach	ned for auto	mated A	ST results				
Phenotypic Confirmation:						Other Results:				
E-test/discs						ESBL E-test Interpretati	on: —			
Antibiotic MIC	Zone diamete	er In	terpretati	lon			_			
Ertapenem						Other Tests and Interpr	etation:			
Meropenem		\top				other lesis and interpr	ctation:			
Imipenem						CDO DCD L-tt-"	_			
Rosco Disc Interpretation:						CPO PCR Interpretation	ı:			

Form PHBM_225_2001F Version 1.1 05/2017

BAM BAM

Revised January 17, 2024 Page 13

Appendix C - Surveillance Form for Carbapenemase-Producing Organisms (CPO) OR *Candida* auris (C. auris) Identified in Acute Care Facility

1	Organism CPO OR C. auris If a patient is colonized and/or infected with both CPO and C. auris, please fill out two separate forms for each organism
2	Unique Identifier – assigned by BCCDC Public Health Laboratory (PHL)
3	Patient's status ☐ Inpatient ☐ Other, please specify
4	Date of admission or visit (dd/mmm/yyyy)
5	Name of the facility
6	Status ☐ Infection (please also complete appendix D) ☐ Colonization ☐ Unknown
7	Did the patient travel outside of Canada within the past 12 months?
	☐ Yes. Please specify the name of the country ☐ Country not provided
	☐ No. Please skip Question 8.
	☐ Unknown or patient is discharged. <i>Please skip Question 8</i> .
8	If answered Yes to Question 7, did the patient have a health-care encounter outside of Canada within the past 12 months?
	☐ Yes, an overnight stay in a hospital or undergone medical/surgical procedure outside of Canada
	☐ Yes, other health-care encounter, e.g., visited GP, walking clinic, dentist, ER, etc.
	☐ No health-care encounter ☐ Unknown
9	Did the patient have an overnight stay in a Canadian facility or undergo medical/surgical procedure in Canada (including BC) within the past 12 months? Yes. Please specify the name of the province (s) No. Please skip to question 11. Unknown. Please skip to question 11.
10	If answered Yes to Question 9 and one of the provinces identified was BC, what types of health-care encounters has the patient had in BC in the past 12 months (excluding current admission)? (Check all that apply)
	☐ An acute care unit/facility admission
	☐ A long-term care facility admission
	☐ A medical/surgical procedure in an outpatient setting
	☐ No health-care encounter ☐ Unknown
11	Is the unit/facility in which the patient is currently admitted under investigation for transmission of organism identified in question 1?
	☐ Yes
	□No
	☐ Unknown or patient is discharged
12	Did the patient have contact [minimum 12 hours] with a known case or environmental sources for the organism (CPO or C. auris) identified in question 1 within the past 12 months? (Check all that apply)
	☐ Yes, within an acute care facility
	☐ Yes, within a long-term care facility
	☐ Yes, private household

Revised January 17, 2024 Page 14

	☐ Yes, other <i>please specify</i>
	□ No. Please skip Question 13.
	☐ Unknown. Please skip Question 13
13	If answer Yes to Question 12, what was the nature of the contact? (Check all that apply)
	☐ Roommate ☐ Person in the same unit/facility or house ☐ Health-care provider ☐ Friend/Relative
	☐ Environmental sources (e.g., contaminated sink or other surface, medical equipment, etc.)
	☐ Other, please specify
	□Unknown

Once completed, please send it to PICNet at picnet@phsa.ca

Appendix D – Addendum Form for Carbapenemase-Producing Organisms (CPO) OR *Candida* auris (C. auris) Infections Identified in Acute Care Facility

NB: This form should be complete if a) the case was identified as a CPO or *C. auris* infection; b) the case was initially reported as colonization, and subsequently developed into a CPO or *C. auris* infection within a year from initial identification. Please ensure that the surveillance form for CPO or *C. auris* (*Appendix C*) has been completed for this case.

1	Organism CPO OR C. auris If a patient is colonized and/or infected with both CPO and C. auris, please fill out two separate forms for each organism
2	Unique Identifier – assigned by BCCDC Public Health Laboratory (PHL)
3	Patients' status
4	Date of admission or visit (dd/mmm/yyyy)
5	Name of the facility
6	Date of CPO infection identification (dd/mmm/yyyy)
7	Site(s) of infection ☐ Bloodstream ☐ Urinary tract ☐ Respiratory tract ☐ Wound ☐ Surgical site ☐ Other, please specify
8	Was ICU admission required due to the infection or the complications associated with the infection within 30 days after identification of the infection?
	\square Yes – the patient was admitted to ICU as a result of the infection or complications associated with the infection.
	☐ No — the patient was not admitted to ICU
	\square N/A – patient was already in ICU due to other medical conditions
	☐ Unknown
9	Patient outcome within 30 days after identification of the infection
	\square Patient alive and still in hospital 30 days after identification of the infection
	☐ Patient survived and discharged
	☐ Patient survived and transferred
	☐ Patient died

Once completed, please send it to PICNet at picnet@phsa.ca

Appendix E – Notification of Ongoing Carbapenemase-Producing Organisms (CPO) or *Candida* auris (C. auris) Transmission

Please complete this form for notification of ongoing CPO transmission/C. auris case investigation in your facility or health authority and email to picnet@phsa.ca

A. Notification Information		
Health Authority:	Facility Name:	Unit:
Contact Person:		
Contact Phone:	Email:	
Facility type: Acute Care Hospital	Long-term Care Facility	Other
Is this report: Notification of CPO or Notification of CPO or section C)	r <i>C. auris</i> transmission investig r <i>C. auris</i> transmission investig	• •
B. Investigation Notification		
Organism: CPO C. auris		
Date of the source case* identified (dd	/mmm/yyyy):	_
Date investigation initiated (dd/mmm/	уууу):	
If CPO, please specify:		
Organism (Genus species):		
CPO gene identified (e.g. ND	M, KPC):	
* A case that makes health authority su the first case in the transmission.	uspected of CPO transmission.	It may be or may not be
C. Transmission Investigation Resolved Date investigation closed (dd/mmm/yyy		
Notes:		
Reported by:	Date:	

Once completed, please send to PICNet at picnet@phsa.ca

Appendix F – Letter to Ordering Provider in Response to CPO or *C. auris*Cases Identified in the Community

Date:
Dear Health Care Provider (ordering provider),
Re: Patient Last name, First name; PHN; DOB
Public Health has received laboratory notification that your patient tested positive for a carbapenemase-producing organism (CPO) \square or <i>Candida auris (C. auris)</i> \square - both emerging public health concerns. As per the Public Health Act and the Communicable Disease Regulation, physicians/administrators for laboratories that identify CPO or <i>C. auris</i> are required to report cases to their local medical health officer.
A provincial non-nominal surveillance program is in place to monitor the epidemiology (e.g. risk factors, laboratory data) of CPO and <i>C. auris</i> in BC. Each patient isolate is assigned a unique identifier for this purpose. The unique identifier for your patient is Attached is a surveillance form. We ask that you complete this form to the best of your ability and return it by email to the Provincial Infection Control Network of BC at picnet@phsa.ca.
CPOs and <i>C. auris</i> both pose significant risk to vulnerable patients in health-care facilities. In the case of CPOs, these are multi-drug resistant gram negative bacteria for which antibiotics available to treat infections are very limited. <i>C. auris</i> is an emerging yeast, which is often resistant to at least one class of antifungals. Due to this risk, please request that your patient inform any health-care facility on admission and/or routine health-care encounters (such as hemodialysis, oncology clinics, BMT day care) that they have tested positive for CPO or <i>C. auris</i> . Infection Control measures will be put in place to decrease the likelihood of spreading these bacteria or yeast to other patients.
At this time, little is known about the carriage and clearance of CPO infections in the community after treatment. Follow-up testing of clearance is not recommended, as carriage may return after

Interpretation of this laboratory result should be in context of the overall health of your patient. In the community, patients who test positive for a CPO or *C. auris* do not generally pose a risk to others. Patients should be advised to maintain good personal hygiene and avoid sharing personal items to prevent spread to others. Added precautions are NOT required in the community office setting.

treatment with a carbapenem antibiotic. After treatment for C. auris infections, patients can remain

Attached is a patient information sheet for your patient (CPO or *C. auris* Health file). Further information on CPO is available at BCCDC website. Further information on *C. auris* is available at PICNet website.

colonized, perhaps indefinitely.

Page 22

Appendix G - Enhanced Surveillance Form for Carbapenemase-Producing Organisms (CPO) OR Candida auris (C. auris) Identified in the Community

1	Organism CPO OR C. auris If a patient is colonized and/or infected with both CPO and C. auris, please fill out two separate forms for each organism
2	Unique Identifier – assigned by BCCDC Public Health Laboratory (PHL)
3	Status
4	Date of visit (dd/mmm/yyyy)
5	At what care setting was the patient identified with the organism identified in Question 1?
	Outpatient clinic Emergency room Community health center/clinic
	Long-term care facility GP's office Other, please specify
6	Did the patient travel outside of Canada within the past 12 months?
	Yes, please specify the name of the country Country not provided
	No. Please skip Question 7.
	Unknown. Please skip to question 7.
7	If answered Yes to Question 6, did the patient have a health-care encounter outside of Canada within the past 12 months?
	\square Yes, an overnight stay in a hospital or undergone medical/surgical procedure outside of Canada
	☐ Yes, other health-care encounter, e.g., visited GP, walking clinic, dentist, ER, etc.
	☐ No health-care encounter ☐ Unknown
8	Did the patient have an overnight stay in a Canadian facility or undergo medical/surgical procedure in Canada (including BC) within the past 12 months?
	Yes. Please specify the name of the province (s)
	No. Please skip to question 10.
_	Unknown. Please skip to question 10.
9	If answered Yes to Question 8 and one of the provinces identified was BC, what types of health-care encounters has the patient had in BC in the past 12 months (excluding current admission)? (Check all that apply)
	☐ An acute care unit/facility admission ☐ No health-care encounter
	☐ A long-term care facility admission ☐ Unknown
	☐ A medical/surgical procedure in an outpatient setting
10	Did the patient have contact [minimum 12 hours] with a known case or environmental sources for the organism identified in question 1 within the past 12 months? (Check all that apply)
	☐ Yes, within an acute care facility
	☐ Yes, within a long-term care facility
	☐ Yes, private household
	☐ Yes, other please specify
	□ No. Please skip Question 10.
_	☐ Unknown. Please skip Question 10
11	If answered Yes to Question 9, what was the <i>nature</i> of the contact? (Check all that apply) ☐ Roommate ☐ Person in the same unit/facility or house ☐ Health-care provider ☐ Friend/Relative

Revised January 17, 2024

	☐ Environmental sources (e.g., contaminated sink or other surface, medical equipment, etc.)			
	☐ Other, please specify			
	☐ Unknown			
If the	If the patient was infected, please answer the following questions			
12	Site(s) of infection (Check all that apply) Bloodstream Urinary tract Respiratory tract Wound Surgical site Other, please specify			
13	Was the patient admitted to a BC hospital due to the current infection identified in question 1? Yes, the patient was admitted due to infection. Specify the name of the facility No, the patient was admitted due to other medical conditions. No, the patient was not admitted Unknown			

Once completed, please send by email to picnet@phsa.ca